|
[1]KOWDLEY KV, LAWITZ E, POORDAD F, et al.Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1[J].N Engl J Med, 2014, 370 (3) :222-232.
|
|
[2]SULKOWSKI MS, GARDINER DF, RODRGUEZ-TORRES M, et al.Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection[J].N Engl J Med, 2014, 370 (3) :211-221.
|
|
[3]PAWLOTSKY JM.New hepatitis C therapies:the toolbox, strategies, and challenges[J].Gastroenterology, 2014, 146 (5) :1176-1192.
|
|
[4]CHAYAMA K, HAYESAYES CN, OHISHI W, et al.Treatment of chronic hepatitis C virus infection in Japan:update on therapy and guidelines[J].J Gastroenterol, 2013, 48 (1) :1-12.
|
|
[5]European Association for Study of Liver.EASL recommendations on treatment of hepatitis C 2014[J].J Hepatol, 2014, 61 (2) :373-395.
|
|
[6]AASLD/IDSA HCV Guidance Panel.Hepatitis C guidance:AASLDIDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus[J].Hepatology, 2015, 62 (3) :932-954.
|
|
[7]Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association.The guideline of prevention and treatment for hepatitis C:a 2015 update[J].J Clin Hepatol, 2015, 31 (12) :1961-1979. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.丙型肝炎防治指南 (2015年更新版) [J].临床肝胆病杂志, 2015, 31 (12) :1961-1979.
|
|
[8]GOWER E, ESTES C, BLACH S, et al.Global epidemiology and genotype distribution of the hepatitis C virus infection[J].J Hepatol, 2014, 61 (Suppl 1) :s45-s57.
|
|
[9]SMITH DB, BUKH J, KUIKEN C, et al.Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes:updated criteria and genotype assignment web resource[J].Hepatology, 2014, 59 (1) :318-327.
|
|
[10]MOHD HANAFIAH K, GROEGER J, FLAXMAN AD, et al.Global epidemiology of hepatitis C virus infection:new estimates of age-specific antibody to HCV seroprevalence[J].Hepatology, 2013, 57 (4) :1333-1342.
|
|
[11]THOMAS DL.Global control of hepatitis C:where challenge meets opportunity[J].Nat Med, 2013, 19 (7) :850-858.
|
|
[12]LIANG TJ.Current progress in development of hepatitis C virus vaccine[J].Nat Med, 2013, 19 (7) :869-878.
|
|
[13]MAO YL, WANG H, LI BA.HCV laboratory detection and clinical application[J].Infect Dis Info, 2014, 25 (2) :75-79. (in Chinese) 毛远丽, 王晗, 李伯安.HCV实验室检测方法与临床应用[J].传染病信息, 2014, 25 (2) :75-79.
|
|
[14]LIU SL.Detection of HCV core antigen in the diagnosis of hepatitis C[J].Continuing Med Education, 2014, 28 (4) :44-46. (in Chinese) 刘胜林.丙肝病毒核心抗原的检测在诊断丙肝中的意义[J].继续医学教育, 2014, 28 (4) :44-46.
|
|
[15]LIAO BJ, ZHOU YC, XIE ZC, et al.Clinical application evaluation of some kinds of method in the detection of HCV antibody[J].J Mod Lab Med, 2012, 27 (4) :106-107. (in Chinese) 廖冰洁, 周迎春, 谢在春, 等.几种丙肝抗体检测的临床应用评价[J].现代检验医学杂志, 2012, 27 (4) :106-107.
|
|
[16]LI MX, WANG XL, WU XK, et al.Comparative study on the detection of HCV-antigen, HCV-RNA and HCV-antibody detection[J].J Mod Lab Med, 2012, 27 (4) :55-56. (in Chinese) 李妙羡, 王香玲, 吴晓康, 等.HCV抗原检测与HCV-RNA和HCV抗体检测的比较研究[J].现代检验医学杂志, 2012, 27 (4) :55-56.
|
|
[17]SIMMONDS P, HOL MES EC, CHA TA, et al.Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region[J].J Gen Virol, 1993, 74 (Pt11) :2391-2399.
|
|
[18]YANG R, CONG X, DU S, et al.Performance comparison of the versant HCV genotype 2.0 assay (Li PA) and the abbott realtime HCV genotype II assay for detecting hepatitis C virus genotype 6[J].J Clin Microbiol, 2014, 52 (10) :3685-3692.
|
|
[19]ABE H, HAYES CN, HIRAGA N, et al.A translational study of resistance emergence using sequential direct-acting antiviral agents for hepatitis C using ultra-deep sequencing[J].Am J Gastroenterol, 2013, 108 (9) :1464-1472.
|
|
[20]LARRAT S, VALLET S, DAVID-TCHOUDA S, et al.Naturally occurring resistance associated variants of hepatitis C virus protease inhibitors in poor responders to pegylated interferon-ribavirin[J].J Clin Microbiol, 2015, 53 (7) :2195-2202.
|
|
[21]European Association for Study of Liver;Asociacion Latinoamericana para el Estudio del Higado.EASL-ALEH clinical practice guidelines:non-invasive tests for evaluation of liver disease severity and prognosis[J].J Hepatol, 2015, 63 (1) :237-264.
|
|
[22]European Association for Study of Liver.EASL recommendations on treatment of hepatitis C 2015[J].J Hepatol, 2015, 63 (1) :199-236.
|
|
[23]LONG L, LIU Y, DUAN ZJ, et al.A preliminary assessment of the clinical utility of measuring hepatitis C virus antibody to evaluate infection status[J].Chin J Hepatol, 2015, 22 (4) :244-250. (in Chinese) 龙璐, 刘媛, 段昭君, 等.抗HCV抗体水平在不同HCV感染人群中的临床意义评价[J].中华肝脏病杂志, 2015, 22 (4) :244-250.
|
|
[24]NELSON DR, COOPER JN, LALEZARI JP, et al.All-oral 12-week treatment with dacaltasvir plus sofobuvir in patients with hepatitis C virus genetype 3 infection:ALLY-3 phase III study[J].Hepatology, 2015, 61 (4) :1127-1135.
|
|
[25]LONTOK E, HARRINGTON P, HOWE A, et al.Hepatitis C virus drug resistance-associated substitutions:state of the art summary[J].Hepatology, 2015, 62 (5) :1623-1632.
|
|
[26]LAWITZ E, SULKOWSKI MS, GHALIB R, et al.Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients:the COSMOS randomised study[J].Lancet, 2014, 384 (9956) :1756-1765.
|
|
[27]LAWITZ E, POORDAD FF, PANG PS, et al.Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-na6ve and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR) :an open-label, randomized, phase 2 trial[J].Lancet, 2014, 383 (9916) :515-523.
|
|
[28]UCHIDA Y, KOUYAMA J, NAIKI K, et al.Significance of variants associated with resistance to NS5A inhibitors in Japanese patients with genotype 1b hepatitis C virus infection as evalued using cycling-probe real-time PCR combined with direct sequencing[J].J Gastroenterol, 2015, 51 (3) :260-270.
|
|
[29]SUSSER S, DIETZ J, VERMEHREN J, et al.European RAVs database:frequency and characteristics of RAVs in treatment naive and DAA-experienced patients[J].J Hepatol, 2016, 64 (Suppl2) :s139.
|
|
[30]MAASOUMY B, VERMEHREN J, WELKER MW, et al.Clinical value of on-treatment HCV RNA levels during different approved sofosbuvir-based antiviral regimens[J].J Hepatol, 2016, 65 (3) :473-482.
|
DownLoad: